Drug Information for Strattera (Physicians Total Care, Inc.): 6 ADVERSE REACTIONS

Ads
  • 6.1  Clinical Trials Experience

    STRATTERA was administered to 5382 children or adolescent patients with ADHD and 1007 adults with ADHD in clinical studies. During the ADHD clinical trials, 1625 children and adolescent patients were treated for longer than 1 year and 2529 children and adolescent patients were treated for over 6 months.

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    Child and Adolescent Clinical Trials

    Reasons for discontinuation of treatment due to adverse reactions in child and adolescent clinical trials — In acute child and adolescent placebo–controlled trials, 3.0% (48/1613) of atomoxetine subjects and 1.4% (13/945) placebo subjects discontinued for adverse reactions. For all studies, (including open–label and long–term studies), 6.3% of extensive metabolizer (EM) patients and 11.2% of poor metabolizer (PM) patients discontinued because of an adverse reaction. Among STRATTERA–treated patients, irritability (0.3%, N=5); somnolence (0.3%, N=5); aggression (0.2%, N=4); nausea (0.2%, N=4); vomiting (0.2%, N=4); abdominal pain (0.2%, N=4); constipation (0.1%, N=2); fatigue (0.1%, N=2); feeling abnormal (0.1%, N=2); and headache (0.1%, N=2) were the reasons for discontinuation reported by more than 1 patient.

    Seizures — STRATTERA has not been systematically evaluated in pediatric patients with seizure disorder as these patients were excluded from clinical studies during the product’s premarket testing. In the clinical development program, seizures were reported in 0.2% (12/5073) of children whose average age was 10 years (range 6 to 16 years). In these clinical trials, the seizure risk among poor metabolizers was 0.3% (1/293) compared to 0.2% (11/4741) for extensive metabolizers.

    Commonly observed adverse reactions in acute child and adolescent, placebo–controlled trials — Commonly observed adverse reactions associated with the use of STRATTERA (incidence of 2% or greater) and not observed at an equivalent incidence among placebo–treated patients (STRATTERA incidence greater than placebo) are listed in Table 1. Results were similar in the BID and the QD trial except as shown in Table 2, which shows both BID and QD results for selected adverse reactions based on statistically significant Breslow-Day tests. The most commonly observed adverse reactions in patients treated with STRATTERA (incidence of 5% or greater and at least twice the incidence in placebo patients, for either BID or QD dosing) were: nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence (see Tables 1 and 2).

    Table 1: Common Treatment–Emergent Adverse Reactions Associated with the Use of STRATTERA in Acute (up to 18 weeks) Child and Adolescent Trials
    Adverse Reaction * Percentage of Patients Reporting Reaction
    STRATTERA Placebo
    (N=1597)(N=934)
    Gastrointestinal Disorders
    Abdominal pain **1810
    Vomiting116
    Nausea105
    General Disorders and Administration Site Conditions
    Fatigue83
    Irritability63
    Therapeutic response unexpected21
    Investigations
    Weight decreased30
    Metabolism and Nutritional Disorders
    Decreased appetite164
    Anorexia31
    Nervous System Disorders
    Headache1915
    Somnolence ***114
    Dizziness52
    Skin and Subcutaneous Tissue Disorders
    Rash21
    * Reactions reported by at least 2% of patients treated with atomoxetine, and greater than placebo. The following reactions did not meet this criterion but were reported by more atomoxetine–treated patients than placebo–treated patients and are possibly related to atomoxetine treatment: blood pressure increased, early morning awakening, flushing, mydriasis, sinus tachycardia, asthenia, palpitations, mood swings, constipation. The following reactions were reported by at least 2% of patients treated with atomoxetine, and equal to or less than placebo: pharyngolaryngeal pain, insomnia (insomnia includes the terms, insomnia, initial insomnia, middle insomnia). The following reaction did not meet this criterion but shows a statistically significant dose relationship: pruritus. ** Abdominal pain includes the terms: abdominal pain upper, abdominal pain, stomach discomfort, abdominal discomfort, epigastric discomfort.*** Somnolence includes the terms: sedation, somnolence.
    Table 2: Common Treatment-Emergent Adverse Reactions Associated with the Use of STRATTERA in Acute (up to 18 weeks) Child and Adolescent Trials
    Adverse Reaction Percentage of Patients Percentage of Patients
    Reporting Reaction from Reporting Reaction from
    BID Trials QD Trials
    STRATTERAPlacebo STRATTERAPlacebo
    (N=715)(N=434)(N=882)(N=500)
    Gastrointestinal Disorders
    Abdominal pain *1713187
    Vomiting118114
    Nausea76134
    Constipation **2110
    General Disorders
    Fatigue6492
    Psychiatric Disorders
    Mood swings ***2011
    * Abdominal pain includes the terms: abdominal pain upper, abdominal pain, stomach discomfort, abdominal discomfort, epigastric discomfort.** Constipation didn’t meet the statistical significance on Breslow-Day test but is included in the table because of pharmacologic plausibility.*** Mood swings didn’t meet the statistical significance on Breslow-Day test at 0.05 level but p-value was less than 0.1 (trend).

    The following adverse reactions occurred in at least 2% of PM patients and were either twice as frequent or statistically significantly more frequent in PM patients compared with EM patients: insomnia (15% of PMs, 10% of EMs); weight decreased (7% of PMs, 4% of EMs); constipation (7% of PMs, 4% of EMs); depression1 (7% of PMs, 4% of EMs); tremor (5% of PMs, 1% of EMs); excoriation (4% of PMs, 2% of EMs); conjunctivitis 3% of PMs, 1% of EMs); syncope (3% of PMs, 1% of EMs); early morning awakening (2% of PMs, 1% of EMs); mydriasis (2% of PMs, 1% of EMs).

    Adult Clinical Trials

    Reasons for discontinuation of treatment due to adverse reactions in acute adult placebo–controlled trials — In the acute adult placebo–controlled trials, 11.3% (61/541) atomoxetine subjects and 3.0% (12/405) placebo subjects discontinued for adverse reactions. Among STRATTERA–treated patients, insomnia (0.9%, N=5); nausea (0.9%, N=5); chest pain (0.6%, N=3); fatigue (0.6%, N=3); anxiety (0.4%, N=2); erectile dysfunction (0.4%, N=2); mood swings (0.4%, N=2); nervousness (0.4%, N=2); palpitations (0.4%, N=2); and urinary retention (0.4%, N=2) were the reasons for discontinuation reported by more than 1 patient.

    Seizures — STRATTERA has not been systematically evaluated in adult patients with a seizure disorder as these patients were excluded from clinical studies during the product’s premarket testing. In the clinical development program, seizures were reported on 0.1% (1/748) of adult patients. In these clinical trials, no poor metabolizers (0/43) reported seizures compared to 0.1% (1/705) for extensive metabolizers.

    Commonly observed adverse reactions in acute adult placebo–controlled trials — Commonly observed adverse reactions associated with the use of STRATTERA (incidence of 2% or greater) and not observed at an equivalent incidence among placebo–treated patients (STRATTERA incidence greater than placebo) are listed in Table 3. The most commonly observed adverse reactions in patients treated with STRATTERA (incidence of 5% or greater and at least twice the incidence in placebo patients) were: constipation, dry mouth, nausea, fatigue, decreased appetite, insomnia, erectile dysfunction, urinary hesitation and/or urinary retention and/or dysuria, dysmenorrhea, and hot flush (see Table 3).

    Table 3: Common Treatment-Emergent Adverse Reactions Associated with the Use of STRATTERA in Acute (up to 25 weeks) Adult Trials

    Adverse Reaction *

    Percentage of Patients Reporting Reaction

    System Organ Class/Adverse Reaction

    STRATTERA(N=540)

    Placebo(N=402)

    Cardiac Disorders

    Palpitations

    3

    1

    Gastrointestinal Disorders

    Dry mouth

    21

    7

    Nausea

    21

    5

    Constipation

    9

    3

    Abdominal pain **

    7

    5

    Dyspepsia

    4

    2

    Vomiting

    3

    2

    General Disorders and Administration Site Conditions

    Fatigue

    9

    4

    Chills

    3

    1

    Therapeutic response unexpected

    3

    1

    Feeling jittery

    2

    0

    Investigations

    Weight decreased

    2

    1

    Metabolism and Nutritional Disorders

    Decreased appetite

    11

    2

    Nervous System Disorders

    Dizziness

    6

    4

    Somnolence ***

    4

    3

    Sinus headache

    3

    1

    Tremor

    2

    0

    Psychiatric Disorders

    Insomnia ****

    15

    7

    Libido decreased

    4

    2

    Sleep disorder

    3

    1

    Renal and Urinary Disorders

    Urinary hesitation and/or urinary retention

    7

    1

    Dysuria

    3

    0

    Reproductive System and Breast Disorders

    Erectile dysfunction *****

    9

    1

    Dysmenorrhea ******

    6

    2

    Ejaculation delayed ***** and/or ejaculation disorder *****

    3

    1

    Menstruation irregular ******

    2

    0

    Skin and Subcutaneous Tissue Disorders

    Hyperhidrosis

    4

    1

    Rash

    2

    1

    Vascular Disorders

    Hot flush

    8

    1

    * Reactions reported by at least 2% of patients treated with atomoxetine, and greater than placebo. The following reactions did not meet this criterion but were reported by more atomoxetine–treated patients than placebo–treated patients and are possibly related to atomoxetine treatment: early morning awakening, peripheral coldness, tachycardia, prostatitis, testicular pain, and orgasm abnormal. The following reactions were reported by at least 2% of patients treated with atomoxetine, and equal to or less than placebo: headache, pharyngolaryngeal pain, irritability. ** Abdominal pain includes the terms: abdominal pain upper, abdominal pain, stomach discomfort, abdominal discomfort, epigastric discomfort. *** Somnolence includes the terms: sedation, somnolence. **** Insomnia includes the terms: insomnia, initial insomnia, middle insomnia.***** Based on total number of males (STRATTERA, N=326; placebo, N=260).****** Based on total number of females (STRATTERA, N=214; placebo, N=142).

    Male and female sexual dysfunction — Atomoxetine appears to impair sexual function in some patients. Changes in sexual desire, sexual performance, and sexual satisfaction are not well assessed in most clinical trials because they need special attention and because patients and physicians may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance cited in product labeling are likely to underestimate the actual incidence. Table 3 above displays the incidence of sexual side effects reported by at least 2% of adult patients taking STRATTERA in placebo-controlled trials.

    There are no adequate and well–controlled studies examining sexual dysfunction with STRATTERA treatment. While it is difficult to know the precise risk of sexual dysfunction associated with the use of STRATTERA, physicians should routinely inquire about such possible side effects.

    1 Depression includes the following terms: depression, major depression, depressive symptoms, depressed mood, dysphoria.

    6.2 Postmarketing Spontaneous Reports

    The following adverse reactions have been identified during post approval use of STRATTERA. Unless otherwise specified, these adverse reactions have occurred in adults and children and adolescents. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Cardiovascular system — QT prolongation, syncope.

    General disorders and administration site conditions — Lethargy.

    Nervous system disorders — Hypoaesthesia; paraesthesia in children and adolescents; sensory disturbances.

    Seizures — Seizures have been reported in the postmarketing period. The postmarketing seizure cases include patients with pre–existing seizure disorders and those with identified risk factors for seizures, as well as patients with neither a history of nor identified risk factors for seizures. The exact relationship between STRATTERA and seizures is difficult to evaluate due to uncertainty about the background risk of seizures in ADHD patients.

    Urogenital system — Male pelvic pain; urinary hesitation in children and adolescents; urinary retention in children and adolescents.

  • Drug Information Provided by National Library of Medicine (NLM).
Ads